About Enzon Pharmaceuticals (OTCMKTS:ENZN)
Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn's disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.
Industry, Sector and Symbol:
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Sector: Medical
- Symbol: OTCMKTS:ENZN
- Previous Symbol: NASDAQ:ENZN
- CUSIP: 29390410
- Web: www.enzon.com
- Current Ratio: 21.35%
- Quick Ratio: 30.90%
Sales & Book Value:
- Annual Sales: $8.38 million
- Price / Sales: 1.69
- Book Value: $0.20 per share
- Price / Book: 1.60
- Annual Dividend: $0.15
- Dividend Yield: 46.9%
- Net Income: ($1,120,000.00)
- Net Margins: 4.00%
- Return on Equity: 3.27%
- Return on Assets: 3.12%
- Employees: 5
- Outstanding Shares: 44,220,000
Frequently Asked Questions for Enzon Pharmaceuticals (OTCMKTS:ENZN)
What is Enzon Pharmaceuticals' stock symbol?
Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."
How often does Enzon Pharmaceuticals pay dividends? What is the dividend yield for Enzon Pharmaceuticals?
Enzon Pharmaceuticals declared a dividend on Tuesday, August 15th. Stockholders of record on Wednesday, August 30th will be paid a dividend of $0.15 per share on Thursday, September 28th. The ex-dividend date of this dividend is Friday, September 29th. View Enzon Pharmaceuticals' Dividend History.
How will Enzon Pharmaceuticals' stock buyback program work?
Enzon Pharmaceuticals declared that its Board of Directors has approved a share buyback plan on Wednesday, November 15th 2017, which permits the company to repurchase $200,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 26.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's management believes its shares are undervalued.
How were Enzon Pharmaceuticals' earnings last quarter?
Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) issued its earnings results on Wednesday, August, 10th. The biotechnology company reported $0.02 earnings per share for the quarter. The biotechnology company had revenue of $2.27 million for the quarter. Enzon Pharmaceuticals had a return on equity of 3.27% and a net margin of 4.00%. View Enzon Pharmaceuticals' Earnings History.
When will Enzon Pharmaceuticals make its next earnings announcement?
Who are some of Enzon Pharmaceuticals' key competitors?
Some companies that are related to Enzon Pharmaceuticals include Tonix Pharmaceuticals Holding Corp. (TNXP), Trimel Pharmaceuticals Corp. (TRLPF), Cleveland BioLabs (CBLI), HTG Molecular Diagnostics (HTGM), Catalyst Biosciences (CBIO), Concordia International Corp. (CXRX), Apricus Biosciences (APRI), Cellectar Biosciences (CLRB), Fibrocell Science (FCSC), Eleven Biotherapeutics (EBIO), Aviragen Therapeutics (AVIR), Biocept (BIOC), Check-Cap (CHEK), Soligenix (SNGX), Valeritas Holdings (VLRX), Eyegate Pharmaceuticals (EYEG), DelMar Pharmaceuticals (DMPI) and Argos Therapeutics (ARGS).
Who are Enzon Pharmaceuticals' key executives?
Enzon Pharmaceuticals' management team includes the folowing people:
- Jonathan N. Christodoro, Chairman of the Board (Age 41)
- Andrew D. Rackear J.D., Chief Executive Officer, Secretary (Age 60)
- Richard L. Feinstein, Chief Financial Officer, Vice President - Finance (Age 71)
- Odysseas D. Kostas M.D., Director (Age 40)
- Jennifer I. McNealey, Director (Age 42)
How do I buy Enzon Pharmaceuticals stock?
Shares of Enzon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enzon Pharmaceuticals' stock price today?
One share of Enzon Pharmaceuticals stock can currently be purchased for approximately $0.32.
How big of a company is Enzon Pharmaceuticals?
Enzon Pharmaceuticals has a market capitalization of $14.14 million and generates $8.38 million in revenue each year. Enzon Pharmaceuticals employs 5 workers across the globe.
How can I contact Enzon Pharmaceuticals?
Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at firstname.lastname@example.org.
MarketBeat Community Rating for Enzon Pharmaceuticals (OTCMKTS ENZN)MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Enzon Pharmaceuticals (OTCMKTS:ENZN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Enzon Pharmaceuticals (OTCMKTS:ENZN)
Analysts' Ratings History for Enzon Pharmaceuticals (OTCMKTS:ENZN)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for Enzon Pharmaceuticals (OTCMKTS:ENZN)
Earnings History by Quarter for Enzon Pharmaceuticals (OTCMKTS ENZN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/23/2018|| || || || || || || || |
|8/10/2016||Q3 2016||$0.02||$2.27 million||View||N/A|
|3/18/2013||Q4 2012||($0.11)||$10.01 million||$10.65 million||View||N/A|
Earnings Estimates for Enzon Pharmaceuticals (OTCMKTS:ENZN)
No earnings estimates for this company have been tracked by MarketBeat.com
Current Dividend Information for Enzon Pharmaceuticals (OTCMKTS:ENZN)
|Most Recent Dividend:||9/28/2017|
Dividend History by Quarter for Enzon Pharmaceuticals (OTCMKTS ENZN)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Enzon Pharmaceuticals (OTCMKTS ENZN)
Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 0.12%
Insider Trades by Quarter for Enzon Pharmaceuticals (OTCMKTS ENZN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/28/2016||Carl C Icahn||Major Shareholder||Buy||694,023||$0.41||$284,549.43|| |
|9/19/2013||Robert Lebuhn||Director||Sell||55,926||$1.72||$96,192.72|| |
|8/10/2012||Robert Lebuhn||Director||Sell||1,933||$6.58||$12,719.14|| |
Latest Headlines for Enzon Pharmaceuticals (OTCMKTS ENZN)
Enzon Pharmaceuticals (OTCMKTS ENZN) Chart for Sunday, November, 19, 2017